Sanofi’s Enjaymo, the only approved drug therapy for cold agglutinin disease, is being acquired by Recordati for $825 million upfront. The drug targets a rare blood disorder where the immune system attacks red blood cells, causing anemia. Enjaymo interferes with the process of red blood cell destruction by blocking a complement system protein. Approved in the U.S., Japan, and Europe, the drug generated $79 million in sales last year and is projected to reach peak sales of $328 million. Recordati, known for its rare disease portfolio, sees Enjaymo as complementary to its existing products and expects positive financial contributions from the acquisition.
Source link
Sanofi Drug for Rare Blood Disease Is Heading to Recordati for $825M
